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5Abbreviations
AGM The para-aorta-splanchnopleura region which contributes to the future
aorta, gonads and mesonephros
Bmx Bone marrow tyrosine kinase in chromosome X
Btk Bruton´s tyrosine kinase
CD Cluster of differentiation; cluster determinant
E Embryonic day
EPC Endothelial progenitor/precursor cell
Etk Epithelial and endothelial tyrosine kinase (Bmx)
FAK Focal adhesion kinase
G-CSF Granulocyte-colony stimulating factor
Gfp Green fluorescent protein
GM-CSF Granulocyte-macrophage-colony stimulating factor
HSC Hematopoietic stem cell
Ig Immunoglobulin
IL Interleukin
Itk Interleukin-2-inducible T-cell kinase
Jak Janus kinase
KD "Kinase dead" mutant of a TK
LacZ ß-galactosidase gene
LDL Low-density lipoprotein
LEC Lymphatic endothelial cell
LLC Lewis lung carcinoma
LYVE-1 Lymphatic vessel endothelial hyaluronan receptor-1
M-CSF Macrophage-colony stimulating factor
MMP Matrix metalloproteinase
NG2 Nerve/glial antigen 2
NRTK Non-receptor tyrosine kinase
Pak1 P21-activated kinase 1
PDGF Platelet-derived growth factor
PECAM-1 Platelet endothelial cell adhesion molecule-1 (CD31)
PH Pleckstrin homology
PI-3K Phosphatidylinositol-3-kinase
Prox-1 Prospero related homeobox protein-1
RTK Receptor tyrosine kinase
SH Src-homology
SMA Smooth muscle actin
SMC Smooth muscle cell
Src Rous sarcoma oncogene
STAT Signal transducer and activator of transcription
Syk Spleen tyrosine kinase
Tec Tyrosine kinase expressed in hepatocellular carcinoma
TH Tec homology
Tie Tyrosine kinase with Ig and epidermal growth factor homology domains
TK Tyrosine kinase
6TNF Tumor necrosis factor
TNFR Tumor necrosis factor receptor
Txk T-cell X-chromosome kinase
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
vWF vonWillebrandt factor
WT Wild-type
XLA X-linked agammaglobulinemia
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8Abstract
During embryogenesis, the endothelial and hematopoietic cells share a common
precursor cell, a hemangioblast. This is the origin of both the blood cells in the
hematopoietic system and endothelial cells in the vascular system. Adult bone marrow
has long been known as a reservoir of adult hematopoietic stem cells (HSCs). HSCs are
able to self-renew and produce progeny that can differentiate into the hematopoietic cells
of all the lineages throughout the whole life span of an individual. The differentiation and
maturation of hematopoietic cells is controlled by a complex network of signalling
molecules. In this process, intracellular tyrosine kinases (TKs) play a central role. The
Tec family of TKs includes Bmx TK that is also expressed in the endothelial cells of
arteries. During adulthood, the hematopoietic and endothelial cells share several common
surface markers, such as CD31, CD34 and vascular endothelial growth factor receptors
(VEGFRs). It has been suggested that the adult bone marrow also contains endothelial
progenitor cells (EPCs), resembling embryonic hemangioblasts, which can differentiate
into endothelial cells during postnatal angiogenesis.
In my thesis studies I have studied the properties of adult bone marrow hematopoietic and
endothelial progenitor cells. This work includes studies on the specific role of Bmx,
which is expressed both in hematopoietic and endothelial cells. Bmx turned out to
modulate the differentiation of hematopoietic progenitor cells and to be regulated by
interleukin-3 and granulocyte-colony stimulating factor. Bmx was also shown to be
expressed specifically in the arterial endothelium of mice and Bmx TK was activated via
the endothelial cell receptors Tie-2 and VEGFR-1. The vasculature and hematopoiesis of
Bmx-deficient mice were, however, normal, indicating that the Bmx function is
redundant, with other Tec-family members compensating. To further clarify the
connection between bone marrow stem cells and endothelium, we studied the
contribution of the putative bone marrow-derived EPCs to angiogenesis and
lymphangiogenesis. In the endothelium of newly formed vessels, induced by growth
factors VEGF-A or VEGF-C or an implanted tumor, no bone marrow-derived endothelial
cells could be observed. The results suggest that if there is an EPC compartment in the
adult bone marrow, in these experimental settings it does not contribute to angiogenesis
or lymphangiogenesis in vivo. However, the close relationship of the bone marrow-
derived cells and (lymph)angiogenic vessels, and the occasional presence of a pericyte
marker in the bone-marrow derived cells in angiogenic processes, suggest that these cells
could promote angiogenesis as supporting effector cells or pericytes.
9Review of the literature
1. Development of the hematopoietic and vascular system
1.1. Hematopoiesis
1.1.1. Embryonic hematopoiesis
Hematopoiesis, the formation of blood cells, begins in vertebrates extraembryonically in
the wall of the yolk sac. During primitive hematopoiesis, undifferentiated cells located in
the visceral mesoderm form blood island aggregates. The outer layer of blood islands
starts to flatten and differentiate into endothelial cells, while the centrally located cells
give rise to the primitive erythroblasts (Figure 1). Thus, the first endothelial and
hematopoietic cells arise in a close temporal and spatial association. In mice, primitive
hematopoiesis takes place during days 7-11 of development. In humans it starts at day
15-18 and persists for about 10 weeks, producing almost exclusively erythropoietic cells,
but also some macrophages and megakaryocytes (1). While hematopoiesis in the yolk sac
is still ongoing, an independent wave of blood cell formation, giving rise to definitive
hematopoiesis, is initiated in the embryo proper. It begins in the AGM region (aorta,
gonad, mesonephros region), also called paraortic splanchnopleura (P-Sp), where
hematopoietic stem cells (HSCs) are derived from the ventral wall of the dorsal aorta in a
close association with "hemogenic endothelium" (Figure 1) (2, 3). Definitive
hematopoiesis leads to the development of all the hematopoietic lineages (4).
Figure 1. Suggested differentiation pathways of
endothelial and blood cells from mesoderm during
development. Primitive hematopoiesis (left
pathway) generates primitive erythroblasts (eryp)
and endothelial cells of the yolk sac. Definitive
hematopoiesis (right pathway) leads to production
of all blood cell lineages for fetal liver (FL) and
adult bone marrow (BM) (adapted from Orkin
S.H. and Zon L.I. 2002).
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Later during the embryogenesis the task of hematopoiesis is mainly taken over by the
fetal liver until the time of birth. The origin of the hematopoietic cells that populate liver,
spleen and finally bone marrow, is still controversial. It has been suggested that the
definitive HSCs can be formed both in the yolk sac and AGM region, from which they
migrate into the fetal liver for differentiation. The definitive HSCs then provide for the
development of all the hematopoietic lineages. During adulthood, hematopoiesis
normally occurs in bone marrow with contribution of lymphoid cell maturation in the
thymus and lymphoid tissues (4, 5).
1.1.2. Differentiation of blood cells
HSCs are able to give rise to all the hematopoietic lineages (pluripotency) and to progeny
with identical (or almost identical) proliferative and developmental potential (self-
renewal). In adult bone marrow, only 0.05%-0.5% of the cells are estimated to be HSCs
(6). Differentiation of blood cells is tightly controlled by a network of cytokines and
growth factors, cell-cell interaction molecules and components of extracellular matrix.
Hematopoietic growth factors and cytokines, at first, promote the survival and
proliferation, and therefore expansion, of immature cells; secondly they act to modulate
the lineage decisions of differentiating progenitors.
It is thought that the first lineage decision is the restriction to generate myeloid or
lymphoid progeny and development of common myeloid precursors and common
lymphoid precursors. Myeloid lineage produces granulocytes, monocytes, erythrocytes
and megakaryocytes, while lymphoid lineage produces T- and B-lymphocytes and natural
killer cells (Figure 2) (6).
Figure 2. Differentiation of the
hematopoietic cells. Hemato-
poietic stem cells (HSCs) give
rise to common lymphoid pro-
genitors (CLPs) and common
myeloid progenitors (CMPs).
Granulocyte-macrophage pre-
cursors (GMPs) generate
granulocytes and monocytes,
while megakaryocyte-erythrocyte
precursors (MEPs) give rise to
erythrocytes and cells of
megakaryocytic lineage. Endo-
thelial cells are also thought to
arise from the progeny of HSCs
in adults, but the differentiation
pathway is unclear (adapted from
Weissman I.L. et al 2001).
11
For each lineage, particular regulatory systems occur (7). The best-characterized factors
that induce differentiation towards the granulocytes and macrophages are granulocyte-
colony stimulating factor (G-CSF), granulocyte-macrophage-colony stimulating factor
(GM-CSF) and M-CSF. G-CSF in particular induces the terminal differentiation of
granulocytes, and also activates and promotes survival of mature granulocytes.
Interleukin-3 (IL-3) is known to have an exceptional ability to support expansion of
immature myeloid precursor cells (8). These factors act on the hematopoietic cells by
binding to and activating their transmembrane receptors, like G-CSF-R. The cytoplasmic
part of the receptor then activates intracellular cascades that control cellular
differentiation and development of cell-specific characters.
1.2. Vasculogenesis
1.2.1. Blood vascular system
The development of the vascular system begins, together with hematopoiesis, when
angioblasts surround the blood cells in the differentiating blood islands of the embryonic
yolk sac. The angioblasts start to proliferate and differentiate into endothelial cells in
response to growth factors, and the blood islands fuse to form a primary vascular plexus.
These events are partly controlled by vascular endothelial growth factor (VEGF) and its
receptor VEGFR-2 (9-11). Simultaneously, angioblasts start to organize into endothelial
strands in the embryo proper in order to form dorsal aorta and cardinal veins. The
vascular network further develops by sprouting and dividing of capillaries, in a process
called angiogenesis. The newly formed blood vessels mature and become stabilized by
recruitment of pericytes (12, 13). The origin of vascular pericytes and smooth muscle
cells (SMCs) seems to depend on the location in the embryo (14). Endothelial cells and
SMCs might even have a common VEGFR-2+ vascular progenitor, which would
differentiate into SMCs in response to platelet derived growth factor (PDGF)-BB and into
endothelial cells in response to VEGF (15-17).
1.2.2. Hemangioblast
The close relationship between primitive hematopoiesis and the differentiation of the first
endothelial cells in the yolk sac led to the hypothesis of hemangioblasts, common
mesodermal progenitors for hematopoietic and endothelial cells (Figure 1) (18, 19). The
hemangioblast theory has gained support from the fact that the hematopoietic and
endothelial progenitor cells of embryos express several common genes, including
VEGFR-1, VEGFR-2, CD34, CD31, Scl/Tal-1, Gata and Cbfa2/Runx1/AML1 (20).
VEGFR-2 mutation also blocks the development of both the hematopoietic and
endothelial cell lineages. The most direct evidence of the existence of hemangioblasts has
come from several embryonic stem (ES) cell studies (21). Choi et al. identified an
embryonic precursor cell, which in response to VEGF, generated undifferentiated blast
cell colonies containing endothelial, primitive erythroid and definitive hematopoietic
colonies (22). Nishikawa et al. found a VEGFR-2+ cell in cultured ES cell colonies that
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had both hematopoietic and endothelial potential (23). The hematopoietic system is also
functionally linked to the vascular system, as HSCs stimulate vascular growth by
secreting angiopoietin-1 (24).
1.2.3. Development of arteries
The blood vessels of vascular system are organized into capillaries, arteries and veins.
Compared to veins, mature arteries are characterised by a thicker, more muscular wall, a
necessity due to the higher blood pressure and greater shear stress. The molecular
mechanisms determining the arterial or venous fate of blood vessels have recently begun
to be understood. This determination actually takes place early in embryogenesis, even
before the blood circulation is initiated. Studies of zebrafish and mice have revealed
molecular differences in the endothelial cells of arteries and veins (reviewed in (25). For
example, EphrinB2 is expressed specifically in the endothelium of arteries. EphB4, the
receptor of EphrinB2, is present in the venous endothelium (26, 27). EphrinB2 is required
for the normal development of both the arteries and veins (26, 28). The arterial and
venous fate of endothelial cells may even be determined at the angioblast stage by
expression of the gridlock gene (29). Lately, an increasing number of genes specifically
expressed either in arterial or venous endothelium has been described. Notch receptors
and their ligands, expressed in arteries, play a critical role in the early phases of artery
development. In particular, Notch1, Notch3, Notch4, Delta4, Jagged1, Jagged2, DeltaC
and Dll4 are expressed in the arteries of embryos (30-33). Loss of Notch-signaling also
disrupts arterial-venous differentiation (34).
1.2.4. Lymphatic vascular system
The lymphatic vascular system develops shortly after the establishment of the blood
vasculature. Primitive lymph sacs are formed be sprouting of discrete endothelial cells
from cardinal veins. The peripheral lymphatic system is then spread from these
embryonic sacs by sprouting and assembly into capillary tubes (35-37). The molecular
mechanisms that control the development of the lymphatic system have been recently
begun to be understood (38). Prox-1, a transcription factor, was shown to have a critical
role in the initial lymphatic endothelial cell (LEC) differentiation (39, 40). Inactivation of
VEGF-C, ligand for VEGFR-3, also led to the arrest of lymphatic development during
embryogenesis (41). Another theory proposes LECs arise from mesodermal progenitor
cells and fuse to develop a primary plexus (42). Also, VEGFR-3+ progenitor cells
isolated from human fetal liver can apparently differentiate to LECs in vitro (43).
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2. Regulation of adult neovascularization
2.1. Angiogenesis
In healthy adults, angiogenesis occurs during wound healing, the female reproductive
cycle and in the placenta during pregnancy. Angiogenesis is also related to pathological
conditions, such as cancer, atherosclerosis, ischemic heart and peripheral vascular
disease, psoriasis, rheumatoid arthritis and ocular neovascularization (reviewed in (44)).
In response to the release of angiogenic factors, such as VEGF, by hypoxic cells, the
endothelial cells lose their intercellular connections and pericyte coverage, proliferate,
sprout and migrate to form new capillaries (Figure 3a) (45). Angiogenesis also involves
local increases in vessel permeability, basement membrane degradation and changes in
extracellular matrix structure. It is also often associated with the recruitment of
monocytes and macrophages. These cells secrete chemokines, which further attract
endothelial cells, pericytes, fibroblasts and leukocytes (46). Bone marrow-derived cells
capable of differentiating into endothelial cells have also been suggested as contributing
to the new endothelium. This process is often called postnatal vasculogenesis, which
includes endothelial progenitor cell (EPC) mobilization, homing to target tissue and
incorporation into endothelium (Figure 3b) (47). Newly formed vessels are stabilized by
the coverage of pericytes and SMCs (48).
Figure 3. Mechanisms of the blood
vessel growth. A) Angiogenesis
occurs through sprouting of pre-
existing vessels.  The new
vasculature is stabilized by the
recruitment of smooth muscle cells
(SMCs). B) Bone marrow-derived
EPCs are thought to contribute to
neovascularization by differentiating
into endothelial cells, in a process
called vasculogenesis. C) Collateral
vessel growth, or arteriogenesis,
occurs after an occlusion of a main
artery. Increased shear stress
activates endothelial cells leading to
the recruitment of monocytes (Mφ)
and collateral  vessel  wall
remodel l ing (adapted from
Carmeliet P. 2004).
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2.2. Pericytes
Blood vessels are surrounded by vascular mural cells. In large vessels the mural cells are
generally called smooth muscle cells (SMCs), recognized by the expression of smooth
muscle actin (SMA) and usually organized into multiple layers, whereas in capillaries the
mural cells are more sparse and called pericytes. SMCs are highly specialized cells which
mainly regulate the blood vessel tone and blood pressure (49). Pericytes are a poorly-
characterized cell-type, but they are thought to play a critical role in angiogenesis as they
are observed in the endothelial sprouts (50). Pericytes are thought at least to control the
endothelial cell differentiation and the diameter of capillaries (51). They may also
contribute to the vessel growth by secreting angiogenic molecules such as VEGF (52). In
the retina, a lack of pericytes leads to impairment of vascularization (53, 54 ). PDGFR-ß
plays a major role in the developing pericytes, and blocking its function leads to the
pericyte loss and capillary dilation (55). Pericytes are plastic and can differentiate into
other mesenchymal cell types, such as SMCs, during vascular remodelling. Some recent
in vivo studies suggest that also pericytes might have progenitor cells in the adult bone
marrow (49, 56-58). Markers for pericytes include desmin (59), PDGFR-ß (60) and NG2
(61, 62).
2.3. Arteriogenesis
Occlusions of main arteries occur in the patients with atherosclerotic disease and leads to
peripheral tissue ischemia. Arteriogenesis, the transformation of small pre-existing
collateral vessels into larger arteries, is needed to provide blood flow to the ischemic
tissues. Occlusion results in an acute increase of blood flow and fluid shear stress in
collaterals (Figure 3c). This activates collateral artery endothelium, which starts to
secrete cytokines that attract monocytes/macrophages to the perivascular space leading to
degradation of the media layer of the vessel. Finally, regrowth of the smooth muscle coat
and vessel enlargment will result. (13, 63).
2.4. Lymphangiogenesis
Lymphatic system of adults consists of capillary vessels and collecting ducts, which
transport extravasated fluid from the tissues back to the blood circulation. It also has an
important role in immune responses, as white blood cells and antigens are directed to
lymph nodes via lymphatic vessels. In adults, lymphangiogenesis normally occurs along
with angiogenesis and is associated with certain pathological conditions, such as
lymphatic metastasis and immune rejection against transplants (64, 65). LECs can be
distinguished from blood vascular endothelial cells by specific markers, including
LYVE-1 (66), Podoplanin (67) and Prox-1 (39). It has been speculated that bone marrow
LEC progenitor cells expressing VEGFR-3 could contribute to postnatal
lymphangiogenesis (43).
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2.5. VEGF-family and Angiopoietins
The vascular endothelial growth factors (VEGF-A, -B, -C, -D, -E and PlGF) and their
receptors (VEGFR-1, -2 and -3) are primary regulators of both physiological and
pathological angiogenesis, but they also function in the hematopoietic system. Secreted
VEGF proteins regulate the function of the target cell by binding to and thus activating
their transmembrane receptors, which further mediate the signal intracellularly. VEGF-A
is the most potent angiogenic protein and acts through the tyrosine kinase receptors
VEGFR-1 (Flt-1) and VEGFR-2 (KDR, Flk-1). Both VEGFR-1 and VEGFR-2 are
expressed in endothelial cells and HSCs. VEGFR-1 is also present in mature
monocytes/macrophages. During angiogenesis VEGF-A induces survival, proliferation
and migration of endothelial cells (68, 69), and causes vasodilatation and vessel
permeability (70, 71). VEGF-A also participates in the regulation of bone marrow-
derived cell function, as it is for example a chemoattractant for monocytes and regulator
of myeloid progenitor cells (72, 73).
Lymphangiogenesis is mainly controlled by VEGF-C and VEGF-D via their common
receptor VEGFR-3 (Flt-4) in the lymphatic endothelium (38, 74). In adults, VEGFR-3 is
also expressed in macrophages and in the blood vessel endothelial cells of tumors (75,
76). VEGF-C has been shown to induce LEC growth and migration in vitro (77) and
growth of functional lymphatic vasculature in several mouse models (78-80). Inhibition
of the VEGF-C and VEGF-D binding to VEGFR-3 blocks lymphangiogenesis in
transgenic mice (81).
Angiopoietins and their Tie receptors form another important growth factor family of the
vascular system. Angiopoietin-1 acting through Tie-2/Tek is involved in vessel
stabilization and remodeling by regulating the endothelial cell-pericyte interaction (82).
Blood vessels formed in the presence of angiopoietin-1 in transgenic mice are resistant to
plasma leakage (83). Also, activating mutations of Tie-2 have been linked to the
formation of human venous malformations (84).
3. Tec-family and Bmx tyrosine kinase
Bmx/Etk (Bone marrow tyrosine kinase gene in chromosome X/Epithelial and
endothelial tyrosine kinase) protein is a member of the Tec family of intracellular
tyrosine kinases. Generally, tyrosine kinases regulate a variety of critical cellular
functions such as motility, growth, maturation and differentiation of almost all kinds of
cell types. The human genome contains 518 protein kinase genes, which is 1.7% of all
human genes. So far, at least 90 protein tyrosine kinases (PTKs) have been identified,
which can be sub-divided into receptor tyrosine kinases (RTKs, 58 genes) and non-
receptor or intracellular tyrosine kinases (NRTKs, 32 genes), according to their cellular
location (85). Growth factor and cytokine receptors usually transduce signals from
extracellular stimuli through the cellular membrane usually by phosphorylating NRTKs,
such as Bmx. The activated tyrosine kinases form transduction cascades, which carry the
signal to the nucleus (86).
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3.1. Tec family of tyrosine kinases
The Tec-family consists of Tec, Btk, Itk/Tsk/Emt, Txk/Rlk and Bmx/Etk kinases and is
the second largest family of NRTKs after the Src-family (87). The Tec-family kinases are
characterised by a domain structure with a pleckstrin homology (PH) domain in the N-
terminal part, followed by a Tec homology (TH), Src homology (SH3) and SH2 domains
and a C-terminal catalytic tyrosine kinase domain. Tec kinases are involved in multiple
intracellular signalling pathways and they transduce signals from virtually all types of
cell surface receptors, such as growth factor receptors, cytokine receptors, G-protein
coupled receptors, antigen-receptors, death receptors and integrins. Furthermore, many
intracellular TKs, including Jak, Src, Syk and FAK family members are known to
regulate Tec kinases. Tec kinases tranduce signals downstream by regulating, at least,
phosphatidylinositol-3-kinase (PI3-K), the protein kinase C (PKC) and the phospholipase
C (PLC) gamma pathways (88).
Tec kinases regulate critical cellular functions, such as proliferation, apoptosis,
differentiation and migration. In mammals, they are mainly expressed in hematopoietic
cells, but also in some other cell types. Of the Tec-family members, Btk has gained most
attention because mutations in its gene in humans cause a severe immunodeficiency
disease, called X-linked agammaglobulinemia (XLA) (89, 90 , 91). Lack of circulating
gammaglobulins is caused by a defect in B-lymphocyte differentiation, and decreased
number of mature B-cells and mature plasma cells (92). A mouse model for the disease,
called xid mice, have a point mutation in their Btk PH domain; these, as well as BtkKO
mice display a similar defect in the B-cell lineage (93, 94). Itk is mainly expressed in T-
cells, and Itk deficient mice have impaired T-cell development and proliferation (95). The
Tec gene is expressed abundantly in hematopoietic cells, including T- and B-lymphocytes
and myeloid cells, as well as in endothelial cells. Txk protein is found in T-cell and
myeloid lineage (87). TecKO and TxkKO mice have a normal hematopoiesis without any
obvious defects in immune system (96, 97). However, Itk/Txk double deficient mice have
an enhanced T-cell phenotype, when compared to the ItkKO mice. Tec/BtkKO mice also
have a more severe B-cell phenotype than BtkKO mice, suggesting possible redundancy
for Tec family members in mice (96, 97).
3.2. Bmx tyrosine kinase
Bmx was originally cloned in 1994 from human bone marrow (98). Bmx expression was
first detected in granulocytes and monocytes, including myeloid leukemia cells, and the
expression increased along the hematopoietic differentiation pathway (99, 100). Bmx is
also expressed outside the hematopoietic system, in certain endothelial and epithelial
cells (101).
Bmx protein has been shown to regulate the survival of certain cell types and
tumorigenicity of epithelial tumor cells. Bmx protects prostate cancer cells against
thapsigargin- and photodynamic therapy-induced apoptosis and is required for their
androgen independent growth (102, 103). Bmx activates the Pak1 serine/threonine kinase
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and increases the proliferation of breast cancer cells (104). Bmx has a critical role in
cellular transformation and STAT activation induced by Src (105). Bmx activation also
induces VEGF expression, leading to proliferation and survival of epithelial and
endothelial cells (106). Bmx apparently associates with tumor suppressor p53 through its
SH3 domain, which leads to bidirectional inhibition of Bmx and p53 activity (107).
These data strongly suggest that Bmx has a role in anti-apoptotic signaling. On the other
hand, Bmx can promote the cell death in certain experimental settings. Bmx can sensitize
prostate cancer cells to apoptosis after its caspase-3-induced cleavage (108). It has also
been suggested that Bmx participates in epidermal growth factor (EGF)-induced
apoptosis of breast cancer cells (109). There is also evidence that Bmx regulates cell
migration, which further indicates a role in cancer cells. Bmx was shown to regulate
integrin-mediated migration of metastatic carcinoma cell lines by interacting with focal
adhesion kinase (FAK) (110). The mechanisms by which Bmx controls cell motility
include interaction with Cas (111).
In vitro studies suggest that Bmx might be involved in inflammatory angiogenesis.
Tumor necrosis factor (TNF), a major inflammatory cytokine, activates Bmx through its
receptor TNFR-2 on endothelial cells, and Bmx modulates TNF-induced migration and
tube formation (112). In endothelial cells TNF also induces transactivation between Bmx
and VEGFR-2 (113). Transgenic overexpression of Bmx in vivo in the mouse epidermis
induced an inflammatory reaction, and angiogenesis in the skin, with increased
proliferation of keratinocytes and accelerated wound healing (114).
4. Adult endothelial progenitor cells
The field of stem cell biology has made significant advances during the past few years.
Certain organs, such as bone marrow, intestine, skin, muscle and nervous system, have
been described as containing tissue-specific stem cells able to reproduce the tissue of
their origin. The HSCs of the bone marrow represent the best-characterized stem cell
population, normally functioning to generate all the mature blood cell types. Recently,
researchers have been able to identify multipotential progenitor cells in the adult bone
marrow capable of contributing, not only to blood, but also a variety of other tissues, such
as skin, muscle, pancreas, liver, and epithelium of intestine, lung and kidney (115-120).
Thus, adult stem cells have been thought to be able to transdifferentiate to an
unexpectedly wide spectrum of tissues. This led to hopes that these cells could be used in
the treatment of various human diseases, such as ischemic heart disease or Parkinson´s
disease (121). Yet, the true pluripotency of adult stem cells remains controversial (122).
4.1. Identification of EPCs
As embryonic hematopoietic and endothelial cells were shown to have a common
precursor, the hemangioblast, it was speculated that hemangioblasts, or EPC activity,
might persist also in adults. These bipotential progenitor cells would reside in bone
marrow, get mobilized to the blood circulation, and participate in angiogenesis during
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wound healing or tumor growth for example. Asahara et al. were the first to describe the
isolation of adult EPCs, in 1997. When isolated CD34+ and VEGFR-2+ cells from
peripheral blood were cultured in vitro, they developed endothelial cell characteristics
(123). One problem with these studies was, however, that the antibodies used for the
VEGFR-2 immunofluorescent staining of the cells were directed against the intracellular
domain of this receptor. In another study, the surface of implanted vascular prostheses
got covered by cells with endothelial cell morphology of a transplanted bone marrow in a
dog (124). In subsequent studies, human bone marrow EPC populations were defined as
expressing both HSC markers, such as CD34, and endothelial markers, such as VEGFR-
2/KDR (47, 125). Later, CD133/AC133 has been found to mark human progenitors cells
capable of differentiation into hematopoietic and endothelial cells in vitro (126).  In some
studies, the endothelial phenotype of cultured EPCs has been additionally confirmed by
the uptake of acetylated low-density lipoprotein (LDL) or binding to specific lectins. In
peripheral circulation, EPCs (also called CEPs, circulating endothelial progenitors) have
been suggested as being more mature and differentiated, characterized by expression of
mature endothelial cell markers CD31/PECAM-1 and VE-cadherin, and decreased
expression of CD133 (127). CEPs have been distinguished from circulating mature
endothelial cells, shed off from the vessel wall, by their higher proliferation potential and
late outgrowth (128).
Overall, the true identity of EPCs is still controversial and their possible origins are
many. For that reason numerous different methods of EPC isolation have also been used,
which makes it difficult to compare results from different studies (129). Overall, it has
been speculated that the endothelial cells obtained by in vitro cultivation of isolated
mononuclear bone marrow or peripheral blood cells could be originated from HSCs,
myeloid cells, other circulating progenitors or circulating mature endothelial cells (Figure
4) (130). Recent studies have suggested that there is a subopopulation of EPCs in
monocytes/macrophages, which is actually negative for stem cell marker CD34. These
cells could additionally promote angiogenesis by producing angiogenic growth factors
(131-136). Furthermore, multipotent adult progenitor cells (MAPCs) from bone marrow,
which are distinct from HSCs, (137, 138) and even cardiac c-Kit+ stem cells have been
shown to differentiate into endothelial cells (Figure 4) (139). Confusingly, human adult
EPC populations have also been shown to transdifferentiate in vitro into functional
cardiomyocytes (140).
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Figure 4. Suggested pathways of the EPC differentiation in adults. Endothelial cells are thought to
originate both from the hematopoietic and non-hematopoietic stem cells (adapted from Urbich C. and
Dimmeler S. 2004).
4.2. Role of EPCs in neovascularization
4.2.1. Regulation of EPC function
During the last years, convincing in vivo data have been acquired, mostly from mouse
studies, for the capability of adult bone marrow-derived cells to differentiate into
endothelium and to promote angiogenesis. The lack of definitive markers and functional
assays, however, have made it difficult to study the functional properties of EPCs and to
estimate their number in circulation. The mechanisms of the mobilization and recruitment
of the putative adult EPCs has been argued to be driven by VEGF-A, which is
upregulated in ischemic tissues. VEGF-A would act on its receptors VEGFR-2 and
VEGFR-1 on EPCs and promote their migration to the site of injury (141-143).
Mobilization of EPCs and HSCs by VEGF-A and stroma-derived factor-1 (SDF-1) is
suggested to occur through activation of proteinases, such as matrix-metalloproteinase-9
(MMP-9), and release of soluble kit-ligand/stem cell factor (SCF) in the bone marrow
(144, 145). G-CSF, GM-CSF and angiopoietin-1 have also been shown to mobilize EPCs
(125, 126, 143, 146, 147). The homing and incorporation of EPCs during angiogenesis is
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less well studied, but it is thought to be a multistep process regulated by integrins and
selectins, and includes arrest of the cell within the vessels and its extravasation into the
interstitium (130, 148).
4.2.2. in vivo evidence for EPCs
Although the detailed mechanisms regulating EPC mobilization and incorporation into
new vasculature are unsolved, an in vivo evidence of EPC function has been obtained
from several experimental animal models of angiogenesis, including wound healing, limb
ischemia, myocardial ischemia, endothelialization of vascular grafts, retinal
neovascularization and tumor growth (reviewed in (149)). In most of the studies,
genetically marked bone marrow cells have been transplanted into irradiated recipient
mice, so that the bone marrow-derived cells can be later observed in the tissues of the
transplanted mice. Futhermore, some researchers have used in situ hybridization
techniques to detect Y chromosome DNA sequences in male donor derived cells in
female recipients. In some studies direct intravenous injection or injection to the target
organ of selected bone marrow-derived cells have been used instead (150-152). By using
mice reconstituted with bone marrow cells that express LacZ marker gene under an
endothelial cell specific promoter (VEGFR-2 or Tie-2), Asahara et al. showed
incorporation of bone marrow-derived EPCs into the angiogenic vessels during implanted
tumor growth, wound healing and after myocardial infarction (141). In subsequent mouse
studies, transplantation of ex vivo expanded human EPCs led to their incorporation into
the endothelium and promoted recovery from hindlimb ischemia (142). Intriguingly,
recruitment of bone marrow-derived EPCs was shown to be both necessary and sufficient
for tumor angiogenesis and growth in mice (143, 153). Donor and host bone marrow-
derived endothelial cells were also detected in the myocardial vessels of human patients
after the bone marrow transplantation (154). Regarding these and many subsequent
studies, it has been concluded that during angiogenesis, the endothelial cells originate
both by sprouting from the adjacent blood vessels (angiogenesis) and by recruitment of
bone marrow-derived EPCs or circulating EPCs (vasculogenesis) (149).
The in vivo role of EPCs in lymphangiogenesis has not previously been studied. A
CD34+/CD133+ subpopulation of human stem cells was shown to express VEGFR-3.
These cells have the capacity to differentiate into lymphatic and/or vascular endothelial
cells in vitro. It is speculated that VEGFR-3 expressing lymphatic EPCs could participate
in postnatal lymphangiogenesis (43).
4.3. Alternative explanations for EPCs
In spite of the abundant evidence for EPCs, the true in vivo transdifferentiation capacity
of adult bone marrow stem and progenitor cells and their possible contribution to non-
hematopoietic cells still remains controversial. Indeed, many of the results on the
transdifferentiation capacity of bone marrow progenitor cells have not been able to be
repeated in similar experimental settings by other researchers (155, 156). This is
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especially true for EPC studies.  During the last two years, a number of studies with no
evidence of bone marrow-derived cell contribution in angiogenesis has been published
(Table 1) (157-161). Overall, the incorporation rate of bone marrow-derived cells into
vasculature of ischemic tissues has varied from 0 to 90% in different studies (130).
Transplanted Detection   Detection Confocal   
Reference  Result BM cells of BM cells of ECs microscopy Model of angiogenesis
Bailey
2004 (220)
 Yes Sca1+cKit+Lin- Gfp, LacZ CD31, vWF,
LDL-uptake
Yes Radiation-induced tissue injury
Göthert
2004 (157)
 No Unselected SCL-LacZ CD31 No Tumor (LLC, B6RV2)
Rajantie
2004 (222)
 No Unselected Gfp CD31, CD105,
vWF
Yes Tumor (B16), VEGF-A
Tepper
2004 (223)
 Yes Unselected Gfp, Tie2-LacZ CD31, lectin No Soft tissue ischemia,
wound healing
Ziegelhoeffer
2004 (161)
 No Unselected Gfp lectin, CD34 Yes Hindlimb ischemia
Voswinckel
2003 (160)
 No Unselected Gfp, Flk1-LacZ,
Tie2-LacZ
CD31, CD34,
vWF, lectin
Yes Compensatory lung growth
De Palma
2003 (159)
 No Lin- Gfp, Tie2-Gfp CD31 Yes Tumor (B16, TS/A, N202,
LLC)
Sata
2002 (211)
 Yes Unselected/
Sca1+cKit+Lin-
LacZ CD31 No Mechanical artery injury
Grant
2002 (224)
 Yes Unselected/
Sca1+Lin-
Gfp CD31, MECA32,
factor VII
No Retinal neovascularization
Zhang
2002 (225)
 Yes Unselected Tie2-LacZ vWF No Cerebral ischemia
Lyden
2001 (153)
 Yes Unselected LacZ vWF,
VE-cadherin
No Tumor (LLC, B6RV2),
VEGF-A
Asahara
1999 (141)
 Yes Mononuclear Flk1-LacZ,
Tie2-LacZ
CD31, lectin No Tumor (MCA38), ischemia
of myocardium and hindlimb,
wound healing, ovulation
Table 1. Are adult bone marrow (BM)-derived EPCs contributing to the neovascularization in vivo?
Summary of the recent publications, where incorporation of bone marrow-derived cells to the blood vessel
endothelium has been studied in adult mice after transplantation of genetically marked bone marrow cells.
Table indicates the conclusion (Result) and the methods used for the bone marrow transplantation,
detection of bone marrow-derived cells and endothelial cells (ECs), microscopy and inducing angiogenesis
in each study.
Certain alternative explanations for the reported plasticity have been suggested. Because
in most studies mixed cell populations are used, the identity of the transdifferentiating
cells remains unknown. It is thought that rare fusion events between two cells, rather than
plasticity of a stem cell, can explain some, however not all, of the results where low
number of "transdifferentiation" events have been seen after transplantation of large
number of stem cells. Cell fusion has been reported in contributions of bone marrow cells
into for example hepatocytes, cardiomyocytes and Purkinje neurons, containing both
donor and host nuclei. The most likely blood cell type to fuse has been considered to
come from the myeloid lineage (reviewed in (122)). Another explanation for the
transdifferentiation, or alteration of the lineage specificity of the bone marrow progenitor
cells is the contribution of multiple, distinct stem cells or rare pluripotent stem cells
present in the bone marrow. The idea of multipotent adult progenitor cells (MAPCs) of
the bone marrow giving rise to tissues of multiple germ layer tissues have recently gained
support (162, 163).
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The experimental settings can influence on the outcome remarkably. The contibution of
EPCs might be increased in mice that have immunological or genetic selection against
pre-existing endothelium, such as in kidney transplanted mice or Id-mutant mice,
respectively (164). Also, the irradiation procedure used prior to the bone marrow
transplantation can cause endothelial cell apoptosis and increased replacement with EPCs
(165).
The criticism has been made that in most of the studies on the plasticity of bone marrow
cells, the tissue-specific function of the transdifferentiated cells in the target organ has not
been studied. The results are usually based on antibody stainings and cellular
morphology. Furthermore, when studying the contributions of marked bone marrow cells
to blood vessels, circulating white blood cells contaminate all tissues and are in intimate
association with blood vessels. Unfortunately, the distinction of mature endothelial cells
from hematopoietic cells can also be difficult, as they express common surface markers
and certain myeloid hematopoietic cells have also turned out to both bind lectin and
uptake LDL (149).
Recent results on studies on mouse hindlimb ischemia suggest that the positive responses
may result from the paracrine effects of non-endothelial bone marrow-derived cells,
rather than from the incorporation of EPCs (161, 166, 167). Monocytes, HSCs and
platelets are known to stimulate angiogenesis by secreting several angiogenic molecules,
including TNF-alpha, VEGF-A and VEGF-C (168-172).
5. Therapeutic and clinical aspects
5.1. Tumor vascularization
5.1.1. Tumor angiogenesis
It has long been known that tumors fail to grow without neovascularization, and blocking
the growth of new blood vessels could therefore be used to treat cancer patients.
However, until lately, clinical trials on anti-angiogenic drugs have not given results as
good as those anticipated from studies on mouse tumors (173, 174).
Tumor angiogenesis is initiated when the balance between pro-angiogenic and anti-
angiogenic molecules turns in favor of pro-angiogenesis, for example as a result of
increasing tumor mass and hypoxia. The blood vessels of tumors are abnormal and
heterogenous, and characterized by leakiness and incomplete pericyte coverage. Pericytes
are often found alongside the endothelial cell sprouts suggesting that pericytes might
have an active role in tumor angiogenesis (50). Indeed, increased recruitment of pericytes
by PDGFs is also associated with increased tumor growth rate (175). Tumor-associated
macrophages can also promote tumor angiogenesis, by producing TNF-alpha, VEGF,
PDGF and MMP-9 (reviewed in (176)). Current anti-angiogenesis approaches have been
focusing on the endothelial cells, but targeting pericytes could also have benefits.
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The role of EPCs in tumor angiogenesis has been demonstrated in mouse models (141,
143). Increased numbers of circulating EPCs have also been detected in the blood of
breast cancer and lymphoma patients correlating with plasma levels of VCAM-1 and
VEGF, thus supporting EPC evaluation as a clinically relevant angiogenic marker (177).
Interestingly, endostatin, an angiogenesis inhibitor, was shown to inhibit EPC recruitment
(178). It has been suggested that inhibition of the function or recruitment of EPCs might
indeed provide a novel approach to blocking tumor angiogenesis (153).
On the other hand, transplantation of genetically modified EPCs could be used as a
vehicle to target gene therapy to the tumor vasculature. Isolated embryonal and adult
EPCs, carrying suicide gene, have proved be an effective tool to target tumor vessels in
mice (179, 180). In addition to cancer, EPCs could also be used in atherosclerosis. In
rabbits, neointima formation was inhibited by transplantation of EPCs expressing the
cardioprotective endothelial nitric oxidase (eNOS) transgene (179).
5.1.2. Tumor lymphangiogenesis and lymphatic metastasis
Tumor lymphangiogenesis has been much less studied than tumor angiogenesis (181). It
is known that tumors can send metatasis to regional lymph nodes via the lymphatic
vasculature, and that each tumor type has a characteristic pattern of metastasis into
different target organs via blood or lymphatic vessels. Experimental studies on mice
have, however, proved the effect of VEGF-C overexpression on the tumor
lymphangiogenesis and subsequent lymph node metastasis (reviewed in (182)). It has
been shown that blocking VEGF-C/VEGFR-3 signaling in mice suppresses
lymphangiogenesis and spreading of cancer into the lymph nodes (183, 184). Thus, in
theory, inhibition of this pathway could be used as one strategy to prevent lymph node
metastasis.
5.2. Pro-angiogenic strategies
5.2.1. EPC dysfunction
Under disease conditions, impaired neovascularization has been suggested as resulting
from diminished vascular growth factor production and primary dysfunction of
endothelial cells and their progenitors. So far, EPC dysfunction has been connected to the
vascular complications of diabetes, as the type-1 and -2 diabetic patients have a reduced
number and in vitro angiogenicity of circulating EPCs (185, 186). A strong correlation
between the cardiovascular risk factors and decreased amount of circulating EPCs has
been observed. High risk subjects also had a higher rate of EPC senescence in vitro (187).
The authors speculated that EPCs maintain endothelial function in mature blood vessels,
and that the failure of this function may lead to abnormal vasoreactivity. Correlation has
also been observed between EPCs and cerebral ischemic events (188), congestive heart
failure (189), chronic renal failure (190), systemic sclerosis (191) and smoking (192).
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5.2.2. Adult EPCs for vascular regeneration
Mobilization of EPCs and HSCs from the bone marrow to the angiogenic vessels could
be beneficial during tissue ischemia and vascular trauma. This could offer a new
therapeutic strategy for the vascular regeneration either through mobilization of the
endogenous cells or transplantation of ex vivo expanded exogenous cells. Clinically, stem
cells have so far been proved to be efficient in the regeneration of blood from HSCs and
in the skin replacement by epidermal stem cells. The contribution of stem cells in other
cases has, so far, been consicered too small to have any functional significance (122).
Transient increase in the number of EPCs, recognized by the expression of CD133, VE-
cadherin and VEGFR-2, has been observed in the blood of patients suffering form
vascular trauma, caused by coronary artery bypass grafting or burns (193) and during
early phases of myocardial infarction (194, 195). The vascular repair capacity of EPCs is
thought to be increased by mobilizing them into the circulation by stimulatory factors. At
least following molecules and drugs have been shown to stimulate EPC recruitment:
VEGF-A (196, 197), angiopoietin-1 (143), eNOS (198), G-CSF (199), erythropoietin
(134), SDF-1 (200) and statins (201).
Recently, several human trials have been initiated, where patients with peripheral
ischemic disease have been treated by autologous transplantation of progenitor cells. The
treatment is thought to promote the development of collateral vessels around an occluded
artery. Beneficial effects, such as increased transcutaneous oxygen pressure, pain-free
walking time and diminished rest pain, were achieved in the studies of critical limb
ischemia, where CD34+ or mononuclar cells isolated from peripheral blood were injected
intramuscularly to the limb (166, 202). In another study, an intracoronary infusion of
mononuclear cells after myocardial infarction was associated with increased myocardial
perfusion, myocardial viability and decreased infarct size (203-205). Transplantation of
CD133+ cells, isolated from the peripheral blood, into the infarct area was found to be
safe and to improve ventricular function and perfusion after myocardial infarction (206).
Generally, the underlying cellular mechanisms of the observed clinical effects have not
been studied in the trials, but it has been speculated that the effect could come from the
increased myocardial regeneration or neovascularization. EPCs could also be utilized in
coating the synthetic surfaces of vascular grafts in order to prevent the thrombus
formation (207, 208). Also, genetically manipulated EPCs, transduced with VEGF-A-
adenoviruses, for example, have lately been tested in animal models (reviewed in (209)).
Despite the obtained therapeutic effects, the preliminary studies described above have not
yet answered the questions; does the EPC treatment have long-lasting effects, increased
survival or cause late-onset toxicity (reviewed in (149)).
Finally, it is possible, that EPCs for lymphatic vessels could be used for pro-
lympangiogenic therapy for example in the patients with tissue edema. However, no in
vivo evidence for the existence of lymphatic precursor cells have been presented. Bone
marrow-derived progenitors cells with the capability to differentiate into SMCs have also
been characterized in human and mouse blood (210, 211). These cells might play a role
in the neointima formation in atherosclerosis (212).
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Aims of the study
The specific aims of the study were to clarify:
I. The role of Bmx in the proliferation and differentation of myeloid hematopoietic
progenitor cells in vitro, and how Bmx TK activity is regulated in these cells.
II. The in vivo role of Bmx in the development of mouse hematopoietic and vascular
systems using Bmx deficient mice, and the Bmx expression pattern in the mouse
tissues.
III. The relative contribution of the putative bone marrow-derived lymphatic EPCs
and local pre-existing lymphatic vessels to the tumor lymphangiogenesis.
IV. The role of bone marrow-derived progenitor cells in promoting angiogenesis
induced by tumors or VEGF-A.
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Materials and methods
Detailed description of materials and methods can be found in publications I-IV.
Antigen Antibodies Reference or source Study
Bmx Rabbit polyclonal antiserum against (98) I
human Bmx
Mouse mAb against human Bmx BD Pharmingen II
CD105 Rat mAb against mouse CD105 BD Pharmingen IV
(Endoglin)
CD11b Rat mAb against CD11b BD Pharmingen IV
(Mac-1)
CD31 Mouse mAb against human CD31 Berkeley Antibody I
(PECAM-1) Company
Rat mAb against mouse CD31 BD Pharmingen II-IV
CD45 Rat mAb against CD45 BD Pharmingen III, IV
Desmin Rabbit polyclonal antiserum against DAKO IV
desmin
GFP Mixture of several monospecific rabbit Clontech I
anti-GFP antibodies
HA Mouse mAb against hemagglutinin tag Convance Research I-II
Products
LYVE-1 Rabbit polyclonal antiserum against Dr Michael Jeltsch III
mouse LYVE-1
NG2 Rabbit polyclonal antiserum against NG2 (61) IV
pTyr Mouse mAb against phosphotyrosine Upstate Biotechnology II
residue, clone 4G10
SMA Rat mAb against SMA Sigma-Aldrich II, IV
Tie-1 Rabbit polyclonal antiserum against (226) II
human Tie-1
Tie-2 Goat polyclonal antiserum against human R&D Systems II
 Tie-2
vWF Rabbit polyclonal antiserum  against DAKO IV
mouse/human vWF
VEGFR-1 Rabbit polyclonal antiserum against Dr Masaburni Shibuya II
human VEGFR-1
VEGFR-2 Rabbit polyclonal antiserum against Dr Lena Claesson- II
human VEGFR-2 Welsh
VEGFR-3 Mouse mAb against human VEGFR-3, (227) II
clone 9D9
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Cell line Description Reference or source Study
293T Human kidney epithelial cells expressing ATCC I, II
SV40 T antigen and transforming gene
of adenovirus 5
32D Mouse myeloid progenitor cels ATCC I
B16-F1 Mouse melanoma cells ATCC III, IV
HDMEC Human dermal microvascular PromoCell II
endothelial cells
HUVEC Human umbilical vein endothelial cells (228) I
LEII Mouse lung endothelial cells (229) I
LLC Mouse Lewis lung carcinoma cells ATCC III
WEHI-3D Mouse lymphoblasts ATCC I
Growth factor Description Reference or source Study
hAng-1 Human angiopoietin-1 conditioned 293T II II
medium
hG-CSF Human granulocyte-colony stimulating Drs Riitta Alitalo and I
factor Petri Salven
hIL-3 Human interleukin-3 PeproTech I
hVEGF165 Human VEGF 165 splice isoform R&D Systems II
mIL-3 Mouse interleukin-3 Calbiochem Novabiochem I
mVEGF164 Mouse VEGF 164 splice isoform R&D Systems IV
Method Study
ß-galactosidase staining II
Bone marrow transplantation III, IV
Cell culture I-IV
Cell transfection I, II
Confocal microscopy III, IV
DNA cloning I, II
Flow cytometry I
Fluorescent microlymphography III
Generation of transgenic mice II
Growth factor injections IV
Growth factor stimulation I, II
Immunohistochemistry II-IV
Immunoprecipitation II
Isolation and analysis of bacteriophage lambda colonies II
Kinase assay I, II
Lectin perfusion staining II
May-Grünwald Giemsa staining of cytospins I
MTT assay I
Northern blotting I
PCR I
RNA extraction I, II
RT-PCR II
Southern blotting II
Tumor cell transplantation III, IV
Viral gene delivery III
Western blotting I, II
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Results and discussion
I. Bmx regulates differentiation of myeloid progenitor cells
Mouse myeloid progenitor cell line 32D was used to study the role of Bmx in the
differentiation of granulocytes in vitro. We transfected 32D cells to obtain stable cell
lines overexpressing wild-type Bmx (BmxWT) or "kinase-dead" Bmx (Bmx-KD), an
inactive form of the Bmx tyrosine kinase. When the cultured 32D cells were stimulated
with IL-3 or G-CSF, the kinase activity of Bmx increased in both cases. Activation of
Bmx TK was blocked by phosphatidylinositol-3-kinase (PI-3K) inhibitors, Wortmannin
and LY294002, indicating that it requires PI3-K. Bmx was also translocated to cell
membranes upon co-expression with catalytically active PI3-K in transfected endothelial
cells.
Next, the role of Bmx in the differentiation and survival of 32D cells was studied. Both
IL-3 and G-CSF promoted the survival of the 32D cells, but only G-CSF made them
differentiate into granulocytes. BmxWT or BmxKD transfected 32D cells showed similar
growth curves upon stimulation with IL-3. When the cells were stimulated with G-CSF,
Bmx-KD transfected cells continued to proliferate and differentiated into granulocytes,
while the Bmx-WT transfected cells went into apoptosis.
The results indicate that Bmx regulates the balance between apoptosis and differentiation
of hematopoietic progenitor cells. Bmx is known to be expressed in mature cells of
myeloid lineage, and thus might be involved in functional regulation of differentiated
myeloid cells rather than more immature cells (99). Bmx has been observed to induce
both survival and apoptosis also in other cell types. What determines the function of Bmx
in these opposite biological events is not known. However, it has been suggested that Tec
family kinases can play distinct roles, depending on the cell type and the stage of
differentiation (213).
II. Bmx has a redundant role in the endothelium of arteries
Bmx-deficent or Bmx gene targeted ("knock out" or KO) mice were generated by
replacing the first coding exon of Bmx gene by LacZ marker gene by homologous
recombination in ES cells. The BmxKO mice developed normally and were healthy and
fertile without any apparent abnormal phenotype. The sites of the Bmx-promoter driven
LacZ expression in the embryos and adult tissues were determined by ß-galactosidase
staining. The embryos 10.5 days post coitum were negative for the Bmx-LacZ signal, but
at E12.5 a strong positive signal was seen in the endocardium and endothelium of the
largest arteries, such as the aorta, the carotid arteries and the umbilical artery (Figure 5a).
The signal was weaker in the smaller and more peripheral arteries and absent in the
capillary endothelial cells. Later during embryogenesis, expression was found in the same
sites as at E12.5. In the veins, only a weak signal could be seen in the endothelium of the
superior and inferior vena cava near the heart.
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In adult mice, positively stained arterial endothelium was found throughout the body,
such as in coronary arteries (Figure 5b) and SMA-positive vessels of the brain.
Capillaries were negative, while the endothelium of veins was weakly positive only in the
vena cavae. Outside the cardiovascular system, Bmx-LacZ expression was observed only
in epithelioreticular cells of the thymus, and occasionally in epithelial cells of the mucous
membrane of the tongue. The histological analysis of blood vessels did not reveal any
defects in the arteries, despite a deficiency of Bmx TK in the endothelial cells. Nor were
any differences observed between BmxKO and wild-type mice in differential counts of
blood leukocytes. We concluded that this indicates redundancy for Bmx functions.
Figure 5. Bmx expression in the
mouse tissues. A) During embryo-
genesis, Bmx is expressed (blue
signal) in the heart (asterisk) and
major arteries, such as aorta
(arrow), as seen in ß-galactosidase
staining of E12.5 embryos. B)
Also in adult mice, Bmx
expression is specific for the
endothelial cells of arteries. In the
heart, the coronary artery (arrow)
is positive for Bmx, while the vein
(arrowhead) is negative.
We next investigated if Bmx TK can be activated by endothelial cell RTKs Tie-1, Tie-2,
VEGFR-1, VEGFR-2 or VEGFR-3. In the co-transfection experiments of 293T cells only
Tie-2 and VEGFR-1 increased phosphorylation and kinase activity of Bmx TK. The
ligands of these receptors, angiopoietin-1 and VEGF, were also able to activate the
endogenous Bmx in cultured human microvascular endothelial cells.
Bmx appears to be the first intracellular kinase found to be relatively specific for arterial
endothelial cells. Bmx expression starts in embryos between E10.5 and E12.5, suggesting
that Bmx does not participate in the initial phases of vasculogenesis or arteriogenesis.
Althought the vasculature was normal in Bmx-deficient mice, the expression pattern of
Bmx suggests that it may still have a role in pathological conditions associated with
arteries, such as atherosclerosis or collateral artery growth. According to these data, the
Bmx promoter could also be used as a tool to target gene expression specifically to the
endothelium of arteries. We also found that Bmx is involved in the endothelial cell
signaling, as it was activated by two endothelial cell receptors, Tie-2 and VEGFR-1.
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III. Bone marrow-derived cells do not incorporate into lymphatic endothelium
during lymphangiogenesis.
Several mouse studies had shown that adult bone marrow-derived EPCs can promote
postnatal angiogenesis. However, the possible existence of bone marrow-derived
lymphatic EPCs has not been previously studied. We therefore wanted to clarify the
relative contributions of the pre-existing lymphatic network and bone marrow-derived
cells to tumor lymphangiogenesis and lymphatic metastasis.
The contribution of adult bone marrow-derived EPCs to lymphangiogenesis was studied
using mice transplanted with green fluorescent protein (Gfp)-expressing bone marrow
cells. Gfp+ bone marrow cells were isolated from the femurs of transgenic mice that
express Gfp in virtually all cells, as it is placed under the ß-actin promoter (214).
Unfractionated bone marrow cells (2x106 cells per mouse) were injected intravenously
into sublethally (4 Greys) irradiated isogenic C57Bl/6J mice. Lymphangiogenesis was
induced 5 weeks later, by injecting B16 melanoma or LLC lung carcinoma cells
subcutaneosly (s.c.) into the mice and allowing the tumors to grow for 2-3 weeks. In
another group of mice, new lymphatic vessels were generated by s.c. injection of adeno-
associated viruses (AAVs) encoding VEGF-C. White blood cells of the peripheral blood
were 80-95% Gfp+, indicating that the transplantation was successful.
Extensive recruitment of Gfp+ bone marrow-derived cells was observed in the
peritumoral area of the growing tumors (Figure 6a and b). When the tissues were whole-
mount stained with LEC specific LYVE-1 antibodies and analyzed by fluorescent
microscopy, the bone marrow-derived cells were consistently seen intermingled with the
sprouting peritumoral lymphatic vessels. Surprisingly, the endothelium of the tumor-
associated vessels was negative for Gfp. This was further confirmed by analyzing the
tissues by confocal microscopy. After thorough analysis of tens of tumor samples, no
bone marrow-derived LECs were found. The majority of the Gfp+ cells was positive for
CD45, a panleukocyte marker, indicating that the cells were mainly leukocytes.
Lymphangiogenesis was also induced by a single s.c. injection of AAV-VEGF-C into the
mouse ears. Again, no bone marrow-derived cells were incorporated into the growing
lymphatic endothelium.
We also showed the significance of pre-existing vessels in tumor lymphangiogenesis and
lymphatic metastasis. The degree of tumor lymphangiogenesis correlated with pre-
existing lymphatic vessel density in the peritumoral area. In heterozygous VEGF-C-KO
mice, which have hypoplasia of the lymphatic network, the tumor-associated lymphatic
vessels were fewer and leaky when compared to wild-type control mice. Lymphatic
metastasis to regional lymph nodes also failed to occur in these mice, while 25 of the 35
control mice had lymph node metastasis. Finally, K14-VEGFR-3-Ig mice that lack any
cutaneous lymphatic vessels, did not develop any tumor-associated lymphatic vessels.
There was no significant difference in the tumor blood vessel density or the primary
tumor weight between the three groups of mice. Taken together, our data demonstrate
that the newly formed lymphatic vessels sprout from the pre-existing local lymphatic
network without incorporation of bone marrow-derived EPCs.
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These data suggest , surprisingly, that bone marrow-derived cells do not incorporate into
the lymphatic endothelium at all, at least in our models of lymphangiogenesis. In the
previous studies by other groups with similar experimental settings, incorporation of
EPCs into tumor-induced blood capillaries has been detected (reviewed in (215)). As a
conclusion, we could not find any evidence for adult lymphatic EPCs. The results on
tumor lympangiogenesis and metastasis of VEGF-C-KO and VEGFR-3-Ig mice are
consistent with previous observations, that blocking VEGFR-3 signaling suppresses
lymph node, but not lung metastasis (184). The results on bone marrow-derived cells may
have implications for strategies to block lymphangiogenesis and lymph node metastasis
in human cancers and may be important in the field of stem cell biology.
IV. Bone marrow-derived cells recruited during angiogenesis comprise precursors
for periendothelial vascular mural cells.
There has been controversy about the true in vivo contribution of EPCs to the newly
formed blood vessels. We decided to use multichannel confocal laser microscopy and
fluorescent whole mount immunostaining techniques to study the in vivo angiogenic
capacity of adult bone-marrow progenitor cells.
Figure 6. Contribution of Gfp-
marked bone marrow-derived cells to
the tumor neovascularization. A and
B) Gfp+ bone marrow-derived cells
(green) are intermingled with the
sprouting lymphatic vessels (red,
LYVE-1 staining), but are not
incorporated into the lymphatic
endothelium. Dotted lines show the
tumor position. C and D) Gfp+ cells
are closely associated with the tumor
blood vessels (red, CD31 and vWF
stainings). However, bone marrow-
derived Gfp+ endothelial cells are
not present.
We used the same chimeric mice as in the previous study (III), where unfractioned bone
marrow cells expressing the Gfp-marker gene were transplanted into irradiated mice.
Tumor angiogenesis was initiated by s.c. implantation of mouse B16 melanoma cells.
Alternatively, blood vessel growth was induced by repeated s.c. injections of angiogenic
murine VEGF-A into the the ear.
The amount of Gfp+ bone marrow-derived cells was consistently increased at the sites of
angiogenesis (Figure 6c and d). Blood vessels were visualized in the whole mount tissues
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and tissue sections stained for the endothelial cell markers CD31, vWF or CD105. When
the samples were studied by confocal microscopy, clear neovascularization with
recruitment of Gfp+ cells in the tissues was observed, but the endothelial cells were in all
cases negative for Gfp. Instead, bone marrow-derived cells were found in very close
contact with capillaries and endothelial sprouts, and displayed morphology of the
pericytic cells described in tumor angiogenesis. Most of the Gfp+ cells, but not all,
coexpressed the panhematopoietic marker CD45 or the inflammatory monocytic cell
marker CD11b/Mac-1. This suggests that the tissues also contained bone marrow-derived
non-hematopoietic cells. Subpopulations of the Gfp+ cells expressed NG2 proteoglycan,
a marker for pericytes or mural cells. Gfp+ cells were not positive for desmin or SMA,
other pericyte/SMC markers. We concluded that bone marrow-derived cells, at least in
our mouse models, do participate in angiogenesis. However, they do not differentiate into
endothelial cells, but a subpopulation may differentiate into vascular mural cells, and
possibly function as certain types of effector cells.
These data provide an alternative explanation for the bone marrow cell contribution to
angiogenesis. Pericytes are a heterogenous cell population, and their ontogeny is
unknown. Some evidence exists that at least SMCs have progenitor cells in blood
circulation (49). The lack of the SMA signal in the Gfp+ cells could be explained by the
fact that the smooth muscle markers are expressed in more differentiated mural cells (62,
216), while NG2 marks developing pericytes (61, 62, 217, 218). However, this study
does not exclude the possibility that EPCs exist and might differentiate into endothelial
cells under some in vitro culture conditions, and might have in vivo function in other
experimental models, such as mice that have a genetic or immunological selection against
pre-existing endothelium (164).
In our angiogenesis models, we could not find a single conclusive Gfp+ endothelial cell
in the blood vessels. Thus we speculate that the bone marrow-derived endothelial cells
desribed in earlier studies may actually be mural cells or leukocytes, which are in a very
intimate contact with the underlying endothelial cells. In order to distinguish "pseudo
double-labeling", in the case of two distinct overlapping cells in the same tissue section,
from a single cell, it is essential to use confocal microscopy instead of conventional
microscopes. Nor are any of the endothelial cell markers, such as CD31, vWF and
VEGFR-2, which are generally used to recognize endothelial cells in tissues, completely
specific for endothelial cells, but they do also recognize subpopulations of hematopoietic
cells. Bone marrow-derived cells that contribute to angiogenesis can actually be
leukocytes, which promote angiogenesis by secreting angiogenic factors, but do not
transdifferentiatiate into endothelium (219). Similar results to ours have recently been
obtained from other mouse studies, including tumor angiogenesis, collateral artery
growth and compensatory lung growth, where no evidence for EPCs has been found
(Table 1) (157-161). It has been argued that incomplete bone marrow transplantation,
depending on the dosage of irradiation and the transplanted bone marrow cell population,
could explain the different results. However, Gfp+ white blood cells (80-95% of total
white blood cells) observed in the blood and bone marrow of our mice five weeks after
transplantion indicate succesful hematopoietic stem cell transplantation.
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Concluding remarks
In this thesis, work dealing the biological function of a particular signalling protein,
called Bmx, in hematopoietic progenitor cells and vascular endothelium is presented.
More generally, the ability of bone marrow progenitor cells to contribute to the growth of
vasculature was studied.
Hematopoiesis is controlled by a complex network of signalling cascades. One part of
these cascades are the intracellular kinases, which regulate many critical cell functions.
Cellular apoptosis, survival and differentiation are particularly important, as they are
often disturbed in hematological malignancies. We found that Bmx transduces signals
from hematopoietic cytokine receptors and regulates the apoptosis and differentiation of
myeloid progenitor cells. In the vascular system, Bmx was found to have a restricted
pattern of expression in the arterial endothelium, and to be activated by two endothelial
growth factor receptors. We conclude that Bmx function in hematopoiesis and endothelial
cells may be redundant under physiological conditions, as Bmx-deficiency did not cause
any apparent defects.
Hematopoietic stem cells in adult bone marrow are known by their ability to provide all
the blood cells throughout an individual´s whole life. New and exciting discoveries on
adult stem cells have generated enthusiasm and expectations for novel breakthrough
treatments of a variety of diseases. Stem cells in the bone marrow have been suggested as
a source of non-hematopoietic tissues and tool for tissue regeneration. When it comes to
EPCs, many essential questions are still unanswered, including their molecular definition
and relative contribution to postnatal neovascularization. However, the high expectations
have stimulated entry into clinical phase I trials. Results presented in this thesis, and by
certain other laboratories, are in conflict with previous reports. We could find no
evidence for the previously reported in vivo differentiation capacity of bone marrow
EPCs. However, the results do not rule out the potential effects of bone marrow-derived
cells in promoting angiogenesis. On the basis of recent findings we can assume that stem
cells might provide a promising tool for therapeutic revascularization. These cells may
not contribute directly to de novo endothelium, but do provide cells that function as
supporing pericytes or cells that modulate angiogenesis by secreting angiogenic factors.
On the other hand, by blocking this function or by using these cells for delivery of drug
genes to the tumor vasculature, tumor growth might be suppressed.
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